Market Currents
Jazz Pharmaceuticals (JAZZ) clocks a 14.7% gain after reporting Q2 revenue and adjusted EPS of...
-
Friday, July 29, 2011, 2:17 PM ETJazz Pharmaceuticals (JAZZ) clocks a 14.7% gain after reporting Q2 revenue and adjusted EPS of $64.6M (+60%) and $0.82, beating a consensus of $61.9M and $0.77. Sales of its flagship Xyrem drug for treating cataplexy rose 67% Y/Y. The company now expects 2011 adjusted EPS of $3.15-$3.25, ahead of a $3.07 consensus. (PR)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
